Skip to main content
Signal8

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 424B3 — May 15, 2026

$CEROForm 424B3Filed May 15, 2026, 4:32 PM ET0001213900-26-057853Original filing

Cero Therapeutics Holdings, Inc. filed a prospectus supplement updating its S-1 registration statement with its Q1 2026 10-Q results. The filing reveals severe financial distress, with the company reporting a net loss of $5.9 million and a working capital deficit of approximately $9.8 million for the quarter ended March 31, 2026. The company holds only $857,489 in cash and cash equivalents, leading management to state that these conditions raise substantial doubt about its ability to continue as a going concern.

Key figures

Revenue
0
Total Debt
11463865
Cash Position
857489
Shares Outstanding
36010373
Stock Price
0.027
Warrant Price
0.0038
Accumulated Deficit
96724029
Stockholders Deficit
9258755
Working Capital Deficit
9800000
Net Cash Used In Operations
2800000
Potential Dilutive Shares
294373486
Recent Financing Proceeds
1956166

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 424B3 — May 15, 2026: AI Analysis | Signal8